ALS (Amyotrophic Lateral Sclerosis / Motor Neuron Disease)

Amyotrophic lateral sclerosis is a progressive disease of the motor neurons — the nerve cells that carry signals from the brain and spinal cord to voluntary muscles. As these neurons degenerate and die, the muscles they control weaken, twitch, and waste away (atrophy), and the brain progressively loses the ability to initiate and control voluntary movement. The name describes the pathology: 'a-myo-trophic' means 'no muscle nourishment' (muscles waste when their nerve supply is lost), and 'lateral sclerosis' refers to the hardening/scarring of the lateral columns of the spinal cord where the degenerating upper motor neuron fibers run. ALS is the most common form of motor neurone disease (MND); in the US it is also widely known as Lou Gehrig's disease after the baseball player diagnosed in 1939. It is uniformly progressive and, at present, has no cure — but it is not untreatable: medications modestly slow it, and multidisciplinary care meaningfully improves quality of life and survival.

What distinguishes ALS from most other motor disorders is that it damages both levels of the voluntary-movement pathway. Upper motor neurons (UMNs) originate in the motor cortex and descend through the brainstem and spinal cord; their loss produces 'UMN signs' — spasticity (stiff, tight muscles), brisk/overactive reflexes, and slowed movement. Lower motor neurons (LMNs) run from the spinal cord and brainstem out to the muscles; their loss produces 'LMN signs' — muscle weakness, wasting (atrophy), and fasciculations (visible twitching). The co-occurrence of UMN and LMN signs in the same body regions is the clinical fingerprint of ALS and the basis of its diagnostic criteria. Diseases that hit only one level look different: pure-LMN disorders (like spinal muscular atrophy or, largely, progressive muscular atrophy) lack spasticity, while pure-UMN disorders (like primary lateral sclerosis) lack wasting and twitching. Most people with ALS have a mix, though the balance varies.

ALS characteristically starts in one body region and then spreads, region by region, in a way that often looks anatomically contiguous. About two-thirds of people have 'limb' (spinal) onset: a foot drop, tripping, weakness or clumsiness in a hand (trouble with buttons, keys, handwriting), or a weak/wasting arm or leg, usually beginning on one side. Roughly a quarter to a third have 'bulbar' onset, where the first problems are in the muscles of speech and swallowing — slurred speech (dysarthria), a change in voice, or choking/difficulty swallowing (dysphagia). A small minority present with breathing difficulty or with weight loss. Whatever the start, weakness is typically painless early on and progressive, and over months it extends to neighboring regions. The site of onset matters for prognosis: bulbar onset and respiratory onset generally carry a faster course than limb onset.

Because ALS targets the motor system, several other functions are usually preserved, especially earlier on. The senses (sight, hearing, touch, taste, smell) are typically intact. The muscles that move the eyes are relatively resistant and often work until very late, which is what makes eye-gaze communication technology so valuable. Control of the bladder and bowel and sexual function are usually preserved. The heart muscle and other involuntary (smooth) muscles are not directly attacked. Historically ALS was thought to spare thinking entirely, but that view has been revised: while many people retain normal cognition, up to roughly half have some degree of cognitive or behavioral change, and about 10–15% meet criteria for frontotemporal dementia (FTD) — placing ALS and FTD on a shared spectrum (covered in the Cause section). Knowing what is spared helps families preserve dignity, communication, and connection as motor function declines.

ALS is relentlessly progressive, and being honest about prognosis matters for planning and dignity. Across populations, median survival is roughly 2–5 years from symptom onset (about 3 years on average), and the most common cause of death is respiratory failure as the breathing muscles weaken. However, the variability is enormous and the average hides real hope at the edges: about 10% of people live 10 years or longer, and some far beyond that (the physicist Stephen Hawking lived more than 50 years with the disease). Faster progression is associated with older age at onset, bulbar or respiratory onset, early breathing involvement, prominent UMN-and-LMN burden, and frontotemporal dementia; slower progression with younger onset, limb onset, and longer time from first symptom to diagnosis. None of this is a personal prediction — individual trajectories differ widely. Crucially, 'no cure' is not 'nothing to do': riluzole and (for some) edaravone modestly slow decline, tofersen targets SOD1-ALS, and non-invasive ventilation, nutritional support, and multidisciplinary clinic care each independently improve survival and quality of life.

Terminology varies by country and can confuse families. In the UK and much of the world, 'motor neurone disease (MND)' is the umbrella term for a group of disorders, with ALS the most common type; in the US, 'ALS' is often used for the whole group. Within the spectrum: ALS involves both upper and lower motor neurons. Primary lateral sclerosis (PLS) is a rarer, much more slowly progressive form affecting upper motor neurons only (spasticity without prominent wasting), with a markedly better prognosis. Progressive muscular atrophy (PMA) affects lower motor neurons only; some cases later develop UMN signs and reclassify as ALS. Progressive bulbar palsy (PBP) begins in and predominantly affects the speech and swallowing muscles. These distinctions affect expected course and care, and the boundaries can blur over time as the disease evolves — which is one reason diagnosis is reassessed during follow-up.

The central lesion of ALS is the degeneration and death of motor neurons at both levels of the voluntary movement pathway. In the spinal cord and brainstem, lower motor neurons (including the anterior horn cells and cranial motor nuclei) are lost; in the motor cortex, upper motor neurons (Betz cells) and their descending corticospinal tracts degenerate, leaving the gliosis ('sclerosis') of the lateral columns that names the disease. When a lower motor neuron dies, the muscle fibers it supplied are 'denervated' and waste; nearby surviving neurons initially sprout new branches to 'reinnervate' orphaned fibers, which masks weakness for a time and produces the enlarged motor units and fasciculations seen on EMG — but this compensation eventually fails, and weakness becomes apparent. The disease tends to spread in an anatomically contiguous pattern, consistent with cell-to-cell propagation of pathology. Why motor neurons in particular are vulnerable — they are unusually large, metabolically demanding, and have very long axons — is part of the answer to why ALS happens.

The microscopic hallmark of nearly all ALS is abnormal handling of TDP-43, an RNA/DNA-binding protein normally resident in the cell nucleus. In about 97% of ALS cases, TDP-43 is cleared from the nucleus and accumulates as insoluble, often ubiquitinated aggregates in the cytoplasm of affected neurons (discovered as the major component of these inclusions in 2006). This causes a 'double hit': loss of TDP-43's normal nuclear functions (notably regulating RNA splicing — including repression of 'cryptic exons' such as in the STMN2 and UNC13A genes important to motor neurons) plus a toxic gain of function from the cytoplasmic aggregates. TDP-43 pathology is the unifying feature across sporadic ALS, most familial ALS, and the great majority of frontotemporal dementia — biochemically tying the two diseases together. The notable exceptions are ALS caused by SOD1 and FUS mutations, which generally show SOD1 or FUS aggregates instead of TDP-43, marking somewhat distinct disease pathways. TDP-43 is now a leading target for biomarkers and experimental therapies.

Glutamate is the brain's main excitatory neurotransmitter; in excess it becomes toxic ('excitotoxicity'). In ALS, glutamate handling is disturbed: levels can be elevated in the cerebrospinal fluid, and the astrocytic glutamate transporter EAAT2 (also called GLT-1) — which normally mops glutamate out of the synapse — is reduced in the motor cortex and spinal cord of many patients. Motor neurons are especially vulnerable because some of their AMPA-type glutamate receptors are highly permeable to calcium, and motor neurons have relatively limited calcium-buffering capacity; sustained over-activation floods them with calcium, triggering downstream injury via mitochondrial stress, free-radical generation, and enzyme activation. Excitotoxicity is the mechanistic rationale for riluzole, the first drug shown to extend ALS survival, which reduces glutamatergic transmission. It is considered one contributing mechanism among several, not the whole story.

Motor neurons are large, energy-hungry cells with long axons, making them dependent on healthy mitochondria — and mitochondria function abnormally in ALS, with impaired energy production, disrupted calcium buffering, and structural damage. In parallel, oxidative stress — an imbalance between damaging reactive oxygen species and antioxidant defenses — injures proteins, lipids, and DNA in affected neurons. The link became central when the first ALS gene, SOD1, was identified in 1993: SOD1 (superoxide dismutase 1) is an antioxidant enzyme, and although its mutations cause disease mainly through a toxic gain of function rather than simple loss of antioxidant activity, the finding cemented oxidative biology as a research focus. Mitochondrial failure, oxidative stress, excitotoxic calcium overload, and protein aggregation reinforce one another in a vicious cycle. Oxidative stress is the rationale for the approved free-radical scavenger edaravone (Radicava).

Motor neurons do not degenerate in isolation. The brain's resident immune cells (microglia) and support cells (astrocytes) shift toward a reactive, pro-inflammatory state in ALS, releasing cytokines and reactive species that injure neurons, while losing some of their protective functions. A pivotal concept is that ALS is 'non-cell-autonomous': in mutant-SOD1 mouse models, the disease's onset and progression depend not only on the motor neuron but also on its neighbors — astrocytes and microglia carrying the mutation actively accelerate degeneration, and reducing mutant gene expression in those glial cells slows the disease. Astrocytes in ALS can become directly toxic to motor neurons, and microglial activation correlates with disease burden. Peripheral immune changes and infiltrating T cells also play roles. This glial and immune biology is an active therapeutic target (for example, drugs and trials aimed at calming neuroinflammation).

Beyond the headline mechanisms, ALS research points to several interlocking cellular failures. RNA dysregulation is prominent: many ALS genes (TARDBP/TDP-43, FUS, hnRNPs, and the C9orf72 expansion's RNA products) encode or affect RNA-binding proteins, so when they malfunction the cell's RNA processing, transport, and 'stress granule' dynamics go awry. Proteostasis (protein quality control) fails: the ubiquitin-proteasome system and autophagy-lysosome pathway — the cell's two waste-disposal systems — are overwhelmed or mutated (e.g., in genes like UBQLN2, SQSTM1, VCP, OPTN, TBK1), so misfolded proteins aggregate instead of being cleared. Nucleocytoplasmic transport (the trafficking of molecules between nucleus and cytoplasm) is disrupted, especially in C9orf72 disease. And because motor neurons have extraordinarily long axons, defects in axonal transport — the delivery of cargo along the axon — are particularly damaging. These pathways overlap heavily, which is why ALS is increasingly understood as a convergence of related failures rather than one single cause.

ALS is conventionally split into familial ALS (FALS), where there is a family history, accounting for roughly 10% of cases, and sporadic ALS (SALS), about 90%, where there is not. This division is real but increasingly understood as a spectrum: a pathogenic gene variant can be identified in the great majority of familial cases and still in a meaningful fraction (often cited around 10%) of apparently sporadic cases, partly because of incomplete penetrance (a carrier may have no affected relatives) and small families. The four most important genes — C9orf72, SOD1, FUS, and TARDBP — together explain a large share of familial ALS, with more than 40 ALS-associated genes now described. Most ALS is thought to arise from a combination of genetic susceptibility, aging, and environment rather than a single cause. The practical upshot: family history raises the relevance of genetic counseling, gene-targeted therapies (like tofersen for SOD1) make a genetic diagnosis actionable, and a negative family history does not rule genetics out.

In 2011, researchers discovered that an expanded hexanucleotide repeat — a 'GGGGCC' sequence repeated hundreds to thousands of times — in the C9orf72 gene is the most common genetic cause of both ALS and frontotemporal dementia (FTD). In people of Northern European ancestry it accounts for roughly 40% of familial ALS and 5–10% of sporadic ALS (and a large share of familial FTD), though it is rarer in some other populations such as East Asian. It is the clearest genetic embodiment of the ALS–FTD spectrum: the same expansion in one family can cause ALS in one person, FTD in another, or both together. The expansion is thought to harm cells in three ways at once — loss of the C9orf72 protein's normal function, toxic RNA that sequesters other proteins, and toxic 'dipeptide repeat' proteins made by unconventional translation — and it disrupts nucleocytoplasmic transport. Age at onset is typically 50s–60s but ranges widely. Because it is common and mechanistically distinct, C9orf72 is a major target for antisense and other experimental therapies.

Mutations in SOD1 were the first genetic cause of ALS identified, in 1993, and remain among the most studied — the mutant-SOD1 mouse is the classic ALS animal model. SOD1 variants cause roughly 15–20% of familial ALS and about 1–2% of all ALS, with over 200 different mutations described; presentation often features lower-limb onset and predominantly lower-motor-neuron features, and progression rates vary enormously by specific variant (the A4V/p.Ala5Val variant common in North America is notably aggressive, while some others are slowly progressive). Critically, SOD1 mutations are thought to cause disease through a toxic gain of function — the mutant protein misfolds and becomes harmful — rather than simple loss of its antioxidant role, which is why lowering mutant SOD1 is therapeutic. SOD1-ALS generally shows SOD1 (not TDP-43) aggregates. This biology underpins tofersen (Qalsody), an antisense drug that reduces SOD1 production and became the first therapy targeting a genetic cause of ALS (see Treatment).

FUS (fused in sarcoma) and TARDBP each account for roughly 4–5% of familial ALS (and a smaller fraction of sporadic cases). Both encode RNA/DNA-binding proteins that normally reside mainly in the nucleus, and both diseases involve the protein leaving the nucleus and aggregating in the cytoplasm — underscoring the theme that disrupted RNA handling is central to ALS. TARDBP mutations are notable because TDP-43 (its protein product) is the aggregating protein in ~97% of all ALS, so this gene sits at the heart of the shared pathology, even though inherited TARDBP mutations themselves are uncommon. FUS-ALS stands out clinically: certain FUS mutations cause some of the youngest-onset and most aggressive ALS, including rare juvenile cases, and FUS-ALS pathology features FUS (rather than TDP-43) inclusions. Both genes are being explored as targets for gene-silencing therapies (an antisense drug against FUS, jacifusen, is in development).

Genetic testing has shifted from research curiosity to clinical relevance in ALS. The key driver is actionability: identifying a SOD1 mutation can qualify a person for tofersen (an approved SOD1-targeted therapy), and other gene findings (e.g., C9orf72, FUS) can open eligibility for clinical trials of gene-targeted drugs. Testing is increasingly offered to people with ALS — especially with a family history, younger onset, or relevant features — and sometimes to at-risk relatives. It is paired with genetic counseling because the implications are nuanced: many ALS genes show incomplete penetrance (a carrier may never develop disease), results affect blood relatives, and predictive testing of unaffected family members is a weighty, personal decision with psychological, family, and (in some places) insurance considerations. Counseling helps people understand what a result does and does not mean and supports informed, voluntary choices. Programs and expanded gene panels have made testing more accessible.

ALS and frontotemporal dementia (FTD) — a dementia of personality, behavior, and language rather than memory — were long considered separate, but are now understood as a continuum. The evidence is both molecular and genetic: most ALS and most FTD share TDP-43 proteinopathy, and the C9orf72 expansion causes both (sometimes in the same family or person). Clinically, up to roughly half of people with ALS have some degree of cognitive or behavioral change on careful testing — often executive dysfunction (planning, multitasking, mental flexibility) or behavioral/personality changes such as apathy or loss of empathy — and about 10–15% meet criteria for behavioral-variant FTD. Conversely, a notable fraction of people with FTD develop motor-neuron signs. Recognizing cognitive/behavioral involvement matters practically: it can affect a person's insight into their illness, decision-making capacity, adherence to interventions like ventilation or feeding tubes, and the support caregivers need, so screening for it is now part of good ALS care.

For most people, ALS has no identified trigger, and the studied risk factors are statistical associations rather than proven causes. The clearest non-genetic factors are age (risk rises through the 60s–70s) and male sex (men are at modestly higher risk, especially before menopause-age in women, narrowing later). Among modifiable factors, cigarette smoking is the most consistently replicated environmental risk factor, with a modest increase in risk. Military service has been repeatedly associated with higher ALS risk in US veterans across eras — enough that the US Department of Veterans Affairs recognizes ALS as a service-connected disease for veterans — though the responsible exposure(s) remain uncertain. Other associations under study and debate include certain occupational or environmental exposures (heavy metals such as lead, pesticides, and electromagnetic fields), intense physical activity/elite athleticism, and the cyanobacterial toxin BMAA (proposed from a high-incidence cluster in Guam, but unproven). The honest summary: apart from age, sex, smoking, and genetics, environmental contributors are plausible but not established, and no single factor explains most cases.

ALS is uncommon but not rare. In European and North American populations, annual incidence is roughly 1.5–2.7 new cases per 100,000 people, and point prevalence is on the order of 4–6 per 100,000; lifetime risk is often quoted at about 1 in 300 to 1 in 400. In the United States, the CDC's National ALS Registry and related estimates put the number of people living with ALS at any given time in the range of about 30,000 (with estimates varying by case definition and methodology). Onset most commonly occurs between ages 50 and 70 (mean around the early 60s), although it can occur younger or older; familial cases tend to begin somewhat earlier. Men are affected modestly more often than women overall, a gap that narrows with age. Incidence appears somewhat lower in some populations of African, Asian, and Hispanic ancestry than in those of European ancestry, though differences in case ascertainment complicate comparisons. Global counts are projected to rise with population aging.

There is no single blood test or scan that confirms ALS; diagnosis is a clinical judgment built from the history, a careful neurological examination, electrodiagnostic testing (EMG/nerve conduction), and investigations to exclude conditions that can mimic it. The neurologist looks for the combination of upper motor neuron signs (spasticity, brisk reflexes) and lower motor neuron signs (weakness, wasting, fasciculations) in the same or multiple body regions, with evidence that the problem is progressing and spreading and is not better explained by something else. Because early ALS can resemble many other conditions and the first symptoms are often subtle, diagnosis is frequently delayed — on the order of about 10–16 months from first symptom on average — which is a recognized problem because it postpones treatment, planning, and trial access. Suspected ALS warrants prompt referral to a neurologist, ideally one at a specialized ALS/MND clinic.

To harmonize diagnosis and clinical-trial enrollment, the World Federation of Neurology introduced the El Escorial criteria (1994) and revised El Escorial criteria (Airlie House, 2000). These assess four body regions (bulbar, cervical, thoracic, lumbosacral) and classify diagnostic certainty — clinically possible, probable, or definite ALS — by how many regions show both upper and lower motor neuron involvement. A key limitation was low early sensitivity: many people clearly had ALS but did not yet meet 'definite' criteria. The Awaji criteria (2008) addressed this by treating electromyographic evidence of lower-motor-neuron dysfunction — including fasciculation potentials — as equivalent to clinical signs, substantially increasing sensitivity (especially in bulbar-onset disease) without much loss of specificity. These category-based systems remained complex and somewhat error-prone, motivating the simpler Gold Coast criteria.

The Gold Coast criteria (consensus 2019, published 2020) were developed by an international group — including the World Federation of Neurology, the International Federation of Clinical Neurophysiology, ALS/MND patient organizations, and the ALS Association — to make ALS diagnosis simpler and more sensitive than the multi-tiered El Escorial system. They collapse the categories into a single, dichotomous diagnosis ('ALS' or 'not ALS') requiring: (1) progressive motor impairment documented by history or repeated assessment, preceded by normal motor function; (2) the presence of upper AND lower motor neuron dysfunction in at least one body region, OR lower motor neuron dysfunction in at least two body regions; and (3) investigations excluding other disease processes. EMG abnormalities count as lower-motor-neuron signs. Studies show higher diagnostic sensitivity (around 96%) than the revised El Escorial (~85%) or Awaji criteria, helping people get diagnosed — and into treatment and trials — earlier.

Electrodiagnostic testing is central to confirming the lower-motor-neuron component of ALS and to excluding mimics. Needle electromyography (EMG) samples muscles in multiple body regions and looks for evidence of denervation and reinnervation — fibrillation potentials and positive sharp waves (active denervation), fasciculation potentials, and large, long, unstable motor units (chronic reinnervation). Crucially, EMG can reveal lower-motor-neuron involvement in regions that appear clinically normal, helping demonstrate the widespread process ALS requires. Nerve conduction studies are typically near-normal in motor and sensory amplitudes early (sensory studies are usually normal, since ALS spares sensation) and are used to exclude peripheral neuropathies, multifocal motor neuropathy with conduction block (an important treatable mimic), and neuromuscular-junction disorders. EMG findings are now incorporated directly into the diagnostic criteria (Awaji, Gold Coast).

Part of diagnosing ALS is confidently excluding other disorders, because several mimics are treatable and missing them would be costly. Structural causes such as cervical spondylotic myelopathy or a foramen-magnum lesion can produce a mix of upper- and lower-motor-neuron signs and are excluded with MRI of the brain and spine. Multifocal motor neuropathy with conduction block is an especially important treatable mimic — it causes progressive weakness without UMN signs and responds to immunotherapy — and is identified by nerve conduction studies and antibodies. Other considerations include myasthenia gravis and other neuromuscular-junction disorders (especially in bulbar presentations), inclusion body myositis and other myopathies, Kennedy disease (spinobulbar muscular atrophy), thyroid and parathyroid disorders, vitamin B12 deficiency, heavy-metal toxicity, Lyme disease, HIV-associated and other infections, and paraneoplastic syndromes. Typical workup therefore includes MRI, nerve conduction studies/EMG, and blood tests; the absence of sensory loss, sphincter problems, and eye-movement abnormalities also helps point to ALS.

Classifying onset helps anticipate needs and counsel honestly about prognosis. Limb (spinal) onset — about two-thirds of cases — begins with weakness in an arm or leg and tends to have a comparatively longer course. Bulbar onset — roughly a quarter to a third — begins with dysarthria (slurred speech) and/or dysphagia (swallowing difficulty), is relatively more common in older patients and in women, and on average progresses faster, with earlier nutritional and communication challenges. Respiratory onset is uncommon but important: it presents with breathlessness (often lying flat) or unexplained respiratory failure and carries the most urgent prognosis, sometimes being recognized only when breathing fails. Some classifications also distinguish predominantly upper-motor-neuron or lower-motor-neuron phenotypes, flail-arm and flail-leg variants, and the slowly progressive PLS/PMA ends of the spectrum, all of which have different expected trajectories.

The ALSFRS-R is the most widely used clinical and research instrument for tracking ALS. It rates 12 functions — grouped into bulbar (speech, salivation, swallowing), fine motor (handwriting, cutting food/handling utensils, dressing and hygiene), gross motor (turning in bed, walking, climbing stairs), and respiratory (dyspnea, orthopnea, respiratory insufficiency) domains — each from 4 (normal) down to 0 (no function), giving a total from 48 (normal) to 0. The revised version added respiratory items to the original scale, correcting its under-weighting of breathing. Its real value is in trends: the slope of decline (points lost per month) helps characterize how fast the disease is moving, informs the timing of interventions (such as feeding tubes and ventilation), and serves as a primary endpoint in most ALS clinical trials. Because progression is often roughly linear over stretches, the pre-diagnosis rate of decline is also used to estimate prognosis. It is a functional snapshot, not a substitute for the full clinical picture.

Beyond the continuous ALSFRS-R, two simple staging systems summarize disease burden in stages and are used in research, prognosis, and care planning. King's clinical staging (5 stages) is based primarily on anatomical spread: it counts how many body regions are affected and adds stages for the development of nutritional failure (needing a feeding tube) and respiratory failure (needing ventilation), with stage 5 being death — capturing the early-to-mid course well. The Milano-Torino (MiToS) functional staging instead measures the loss of independence in four key domains derived from the ALSFRS-R (movement/walking, swallowing, communication, and breathing), better differentiating the later, more disabled stages. Because King's emphasizes early spread and MiToS captures late functional loss, they are complementary; both have been shown to predict survival, with the risk of death rising at each successive stage. Staging helps standardize how clinicians and trials describe 'how advanced' a person's ALS is.

Monitoring breathing is one of the most important parts of ALS follow-up because respiratory muscle weakness is the leading cause of death and the main trigger for life-extending interventions. Clinics track respiratory function at regular visits using tests such as forced vital capacity (FVC, often upright and sometimes lying down), sniff nasal inspiratory pressure (SNIP) and maximal inspiratory/expiratory pressures (which can detect diaphragm weakness even when FVC is still relatively preserved), and overnight oximetry or blood gases to detect nighttime under-breathing (hypoventilation). Clinical clues are just as important: breathlessness on exertion or when lying flat (orthopnea), disrupted sleep, morning headaches, daytime sleepiness, and a weak cough. Declining values and these symptoms guide the timing of non-invasive ventilation (which improves survival and quality of life) and cough-assist support, and inform conversations about longer-term ventilation choices. Respiratory measures are also key prognostic markers.

Receiving an ALS diagnosis is life-altering, and the manner of its delivery has a lasting effect on how people cope. Guidelines and patient organizations emphasize breaking the news in a private, in-person setting with enough time, in plain language, ideally with a family member present and a clinician the person can follow up with. Good practice balances honesty about the seriousness and uncertainty of prognosis with realistic hope — emphasizing what can be done (symptom relief, disease-modifying medication, ventilation and nutrition support that extend life and comfort, clinical trials) and that trajectories vary widely between individuals. Information should be paced to the person's readiness rather than dumped all at once, with written resources and reputable contacts offered. Prompt referral to a multidisciplinary ALS clinic and to support organizations, plus an early conversation (when the person is ready) about goals and advance care planning, sets the foundation for the rest of the journey.

Weakness is the core symptom of ALS and the one that ultimately produces most disability. It typically begins in one region — a hand (difficulty with buttons, keys, writing, opening jars), a foot/leg (tripping, foot drop, falls), or the bulbar muscles — and is usually painless at first, which is one reason it can be dismissed early. Over time it spreads to neighboring muscle groups and to the opposite side. As lower motor neurons die, the denervated muscles waste visibly (atrophy), sometimes most obvious in the hands (thinning between the thumb and fingers) or the tongue. Because surviving neurons initially compensate by reinnervating orphaned muscle fibers, measurable strength can lag behind the underlying neuron loss until that reserve is exhausted. The progression of weakness eventually affects walking, transfers, hand use, head control (neck weakness, 'head drop'), speech, swallowing, and breathing.

Spasticity comes from the upper-motor-neuron side of ALS. When the descending corticospinal control is lost, muscles become abnormally tight and resistant to movement, reflexes become brisk or exaggerated, and there may be clonus (rhythmic involuntary contractions) or a positive Babinski sign. Spasticity can make limbs feel stiff and heavy, interfere with walking and use of the hands, cause cramping or painful spasms, and disturb sleep. It often coexists with the weakness and wasting of lower-motor-neuron loss, so a limb may be both weak and stiff. Management combines regular stretching and range-of-motion exercise and physiotherapy with anti-spasticity medications (such as baclofen or tizanidine) when needed, balancing relief of stiffness against not unmasking underlying weakness. Spasticity is more prominent in upper-motor-neuron-predominant forms and primary lateral sclerosis.

Fasciculations are brief, involuntary twitches of small bundles of muscle fibers, visible as flickering under the skin; they arise from irritability of dying or stressed lower motor neurons and are a characteristic feature of ALS, often becoming widespread (including the tongue). Muscle cramps — sustained, painful involuntary contractions — are also frequent and can be an early and ongoing complaint, sometimes occurring in unusual places (thighs, abdomen, hands, tongue). Importantly for the worried-well: isolated muscle twitching without weakness, wasting, or other neurological signs is extremely common and almost always benign (so-called benign fasciculation syndrome); fasciculations matter diagnostically in ALS only in the context of accompanying weakness and atrophy. Cramps may be eased by stretching, hydration, and (when troublesome) medications; there is no single highly effective drug, and options like mexiletine have some supporting evidence for cramp frequency.

Dysarthria — difficulty producing clear speech — is the first symptom in bulbar-onset ALS and develops in most people eventually. It results from weakness and incoordination of the muscles of the tongue, lips, palate, and larynx, combined (in mixed disease) with the strained, effortful quality that upper-motor-neuron involvement adds. Speech may become slurred, slow, quiet, nasal (from palate weakness), hoarse or strained, and progressively harder for others to understand. Over time, some people lose functional speech entirely, even while their thinking and desire to communicate remain intact. This is one reason speech-language therapy, early voice/message banking, and augmentative and alternative communication (AAC) technology are introduced proactively (covered in Therapy) — to preserve the person's voice and ability to communicate as the disease advances. Speech changes can also be emotionally distressing and socially isolating, which support and planning can mitigate.

Dysphagia — trouble swallowing — arises from weakness and incoordination of the tongue, palate, and throat muscles. It can cause coughing or choking on food and liquids, food sticking, longer mealtimes, and a risk of aspiration (food or liquid entering the airway), which can lead to pneumonia. Reduced intake from difficult swallowing contributes to malnutrition and weight loss, themselves linked to faster decline, which is why nutrition is monitored closely and feeding-tube (PEG) placement is discussed before swallowing becomes unsafe. Two related secretion problems are common: sialorrhea (drooling) is not usually overproduction of saliva but failure to swallow normal saliva, leading to pooling and drooling — managed with anticholinergic medications, botulinum toxin injections to salivary glands, or other measures; and conversely, some people struggle with thick, tenacious mucus that is hard to clear, helped by hydration, mucus-thinning strategies, and cough-assist devices. Speech-language pathologists and dietitians guide swallowing strategies, diet texture changes, and timing of interventions.

Because ALS weakens the muscles of respiration — chiefly the diaphragm, plus the chest-wall and accessory muscles — progressive respiratory failure is the most consequential aspect of the disease and the most common cause of death. Importantly, the early signs are easy to miss and often appear first at night, when lying flat increases the load on a weak diaphragm: breathlessness when lying down (orthopnea), frequent waking, vivid dreams or poor-quality sleep, morning headaches (from carbon-dioxide retention overnight), daytime sleepiness and fatigue, reduced appetite, and a weak cough that raises infection risk. As weakness advances, breathlessness occurs with less exertion and then at rest. This is why clinics monitor breathing regularly (see Diagnosis) and introduce non-invasive ventilation (BiPAP) and cough-assist support, which improve both survival and quality of life. Respiratory symptoms also anchor the crucial advance-care conversations about ventilation choices.

Pseudobulbar affect (PBA), also called emotional lability or emotional incontinence, is involuntary, exaggerated, or contextually mismatched outbursts of laughing or crying. Someone may burst into tears or laughter that is out of proportion to, or disconnected from, their actual emotional state — for example crying at something only mildly sad, or being unable to stop laughing. It is a neurological consequence of damage to the corticobulbar (upper-motor-neuron) pathways that normally regulate emotional expression, not a sign of depression or of losing emotional control, and it is common in ALS (especially with bulbar/UMN involvement). Distinguishing PBA from depression matters because they are managed differently, though they can co-exist. Education and reassurance help, and it is treatable: a fixed-dose combination of dextromethorphan and quinidine (Nuedexta) is FDA-approved for PBA, and some antidepressants are also used. Naming the symptom often brings relief to patients and families who found it bewildering.

ALS is no longer considered a purely motor disease. Up to roughly half of people develop measurable cognitive or behavioral changes, most often mild and in the realm of executive function (planning, multitasking, mental flexibility, word-finding) or behavior/personality (apathy, reduced empathy, loss of motivation, sometimes disinhibition or rigid/repetitive behaviors). About 10–15% develop frank frontotemporal dementia (behavioral variant). Memory and orientation are usually relatively preserved compared with Alzheimer's. These changes can be subtle and are often more apparent to family than to the person. They matter practically: cognitive/behavioral involvement can reduce a person's insight into their illness, complicate complex decisions (such as accepting a feeding tube or ventilation), affect adherence to care, and add to caregiver burden — so brief cognitive/behavioral screening is recommended as part of comprehensive ALS care, with support tailored accordingly. (The biological ALS–FTD link is covered in the Cause section.)

ALS spares the sensory nerves, so the disease does not cause pain by directly damaging them — but pain is nonetheless common and often under-treated, arising secondarily from the motor problems. Sources include muscle cramps and spasticity; 'frozen' or aching shoulders and other joints that become stiff and contracted from reduced movement; musculoskeletal strain from altered posture, weak neck muscles, and immobility; pressure discomfort and skin soreness from sitting or lying in one position when a person can no longer reposition themselves; and swelling (edema) in immobile limbs. Pain tends to become more prominent as the disease advances and mobility declines. It is very manageable with a stepwise approach: physiotherapy, stretching, range-of-motion and positioning/seating optimization, treating spasticity and cramps, and analgesics ranging from simple pain relievers to, when needed, stronger medications — the same opioids that also help breathlessness in later stages. Good pain control is a central part of comfort-focused and palliative care.

Fatigue — physical and mental exhaustion beyond ordinary tiredness — is a frequent and quality-of-life-limiting symptom. It has several contributors: weak muscles must work disproportionately hard for ordinary tasks; respiratory muscle weakness causes nighttime hypoventilation that leaves people unrefreshed; and sleep is frequently fragmented. Sleep disturbance in ALS is often driven by treatable problems — breathlessness when lying flat, the inability to reposition during the night, muscle cramps, pooled saliva or secretions, anxiety and low mood, and pain. Identifying and treating the underlying cause is the key: non-invasive ventilation can dramatically improve sleep and daytime energy when nighttime under-breathing is the issue; positioning aids, secretion management, cramp treatment, and addressing mood and pain help others. Energy-conservation strategies and pacing from occupational therapy, plus attention to mood, round out management. Because fatigue and sleep problems compound disability and distress, they are worth raising explicitly with the care team.

Unintended weight loss is common in ALS and is more than a consequence of eating less. It stems from several factors: dysphagia and longer, tiring mealtimes reduce intake; loss of muscle mass lowers body weight; arm and hand weakness makes self-feeding hard; and many people are 'hypermetabolic,' burning calories faster than expected even at rest. Weight loss and a falling body-mass index are independently associated with worse prognosis, while being able to maintain weight (and even a somewhat higher BMI) is associated with longer survival. For these reasons nutrition is treated as an active part of care rather than an afterthought: dietitians monitor weight and intake, recommend calorie- and protein-dense foods and supplements, adjust food textures and thickened liquids for safer swallowing, and help time the placement of a feeding tube (PEG/gastrostomy) before intake or breathing become too compromised — an intervention associated with stabilized weight and supported by clinical guidelines.

It is important to frame ALS drug treatment honestly. As of the mid-2020s, the disease-modifying options are riluzole (the longest-standing), edaravone (Radicava, available where approved), and tofersen (Qalsody) for the small subset with SOD1 mutations; the AMX0035 combination (Relyvrio/Albrioza) was approved and then withdrawn after a larger trial failed. None of these stops or reverses ALS — riluzole and edaravone slow it modestly, and tofersen targets one genetic cause. Because the benefits are incremental, the largest gains in survival and quality of life in ALS still come from multidisciplinary supportive care: non-invasive ventilation, nutritional support, symptom management, and the multidisciplinary clinic model (covered in Therapy). Many people also consider clinical trials. The right framing is realistic hope: there are things that help, the field is unusually active, but families should be wary of any product promising to cure or reverse ALS.

Riluzole was the first medication shown to alter the course of ALS and remains a standard of care. It is thought to work mainly by reducing glutamatergic excitotoxicity (limiting glutamate release and its effects). The pivotal randomized trials and a Cochrane systematic review (four trials, ~1,477 participants) found that riluzole 100 mg/day prolongs median survival by roughly two to three months and probably prolongs the time before a person needs tracheostomy/ventilation, with a reasonable safety profile; some real-world analyses suggest the benefit over the whole disease course may be larger than the trial figure, and benefit may differ by disease stage. It is generally well tolerated; the main considerations are nausea, fatigue/weakness, and elevated liver enzymes (so liver function is monitored). It comes as a tablet and, for people with swallowing difficulty, as an oral suspension or a dissolving film. Guidelines recommend offering riluzole to people with ALS. It slows the disease modestly — it is not a cure.

Edaravone is a free-radical scavenger (antioxidant) approved for ALS in Japan and South Korea (2015) and by the US FDA in 2017, available as an intravenous infusion given in cycles and, since 2022, as an oral suspension. Its approval rested largely on a 24-week randomized Japanese trial (often called Study 19/MCI186-19) that, after an earlier broader trial was negative, enrolled a defined early-stage subgroup with relatively preserved function and breathing and faster progression; in that subgroup, edaravone slowed the decline in ALSFRS-R scores compared with placebo. The honest caveats are significant: the benefit was demonstrated in a narrow, defined population, the long-term and survival benefits are less clear, the treatment is burdensome and costly, and some regulators (notably the European Medicines Agency, where it was not approved for this use) judged the evidence insufficient. It is a legitimate, approved option many people choose, but its magnitude of benefit and best candidates remain debated.

AMX0035 is a fixed combination of sodium phenylbutyrate and taurursodiol, aimed at reducing neuronal stress and death. Its Phase 2 CENTAUR trial (137 participants, NEJM 2020) showed a modest slowing of functional decline (about 2.9 ALSFRS-R points over 24 weeks), and a longer-term analysis suggested a survival benefit. On that basis it was approved in Canada (Albrioza, 2022) and by the US FDA (Relyvrio, September 2022), after an unusual reversal in which an FDA advisory committee initially voted against it. The company had publicly committed to withdrawing the drug if its larger confirmatory trial failed. In March 2024 that trial — the Phase 3 PHOENIX trial (~660 participants) — did fail to beat placebo on the primary endpoint, and Amylyx voluntarily removed Relyvrio/Albrioza from the US and Canadian markets in April 2024 (the FDA formally withdrew approval afterward), while keeping it available to patients already taking it who wished to continue. The episode is widely cited as both a cautionary tale about approving drugs on modest single-trial evidence and an example of a company honoring its commitment when the confirmatory data did not hold up.

Tofersen is an antisense oligonucleotide delivered by intrathecal (spinal) injection that reduces synthesis of the SOD1 protein, addressing the toxic gain of function in SOD1-ALS. Its Phase 3 VALOR trial did not meet its primary clinical endpoint (change in ALSFRS-R at 28 weeks), but it produced large reductions in cerebrospinal-fluid SOD1 (target engagement) and in plasma neurofilament light chain (NfL, a marker of ongoing nerve-cell damage), and the longer open-label extension suggested clinical slowing with earlier treatment. In April 2023 the US FDA granted tofersen accelerated approval — the first treatment to target a genetic cause of ALS — based on the NfL reduction as a surrogate reasonably likely to predict benefit; confirmatory data (including the ATLAS trial in pre-symptomatic SOD1 carriers) are ongoing, and it was subsequently authorized in the EU as well. It applies only to the roughly 2% of people with ALS who carry a SOD1 mutation (hence the importance of genetic testing). It is significant both for those patients and as a proof of concept that gene-targeted therapy and biomarker-based approval can work in ALS.

When stretching and physiotherapy aren't enough, spasticity and painful muscle spasms in ALS are commonly treated with oral anti-spasticity medications — most often baclofen (a GABA-B agonist) or tizanidine (an alpha-2 agonist); benzodiazepines are sometimes used for spasms, and dantrolene less commonly. The key principle is careful titration: because spasticity can paradoxically provide some structural support to weak limbs, over-relaxing the muscles can unmask weakness and worsen function or transfers, so doses are individualized to relieve discomfort and stiffness without removing useful tone. Common side effects include drowsiness and weakness. For severe, refractory spasticity, intrathecal baclofen (delivered by an implanted pump) is occasionally considered. These medications are symptomatic — they ease stiffness and spasm but do not affect the disease itself — and are best combined with a regular stretching and range-of-motion program.

Muscle cramps are common in ALS and can be painful and disruptive. First-line measures are non-drug: regular stretching, gentle exercise and range-of-motion, hydration, and massage. When cramps remain troublesome, medication options are considered, though the evidence base is limited. Mexiletine (a sodium-channel blocker) has randomized-trial evidence for reducing cramp frequency and intensity in ALS at appropriate doses, and is a reasonable option with cardiac caution and monitoring. Other agents sometimes tried include baclofin/tizanidine (which also treat associated spasticity), levetiracetam, and gabapentin, with weaker evidence. Quinine sulfate, historically used for cramps, is generally avoided for this purpose because regulators (including the US FDA) have warned about serious risks (such as severe blood disorders) that outweigh its modest cramp benefit. As always, choices are individualized and weighed against side effects by the prescriber.

Sialorrhea (drooling) in ALS usually reflects a failure to clear normal saliva rather than overproduction, but reducing saliva volume helps. First-line treatments are anticholinergic medications that dry secretions — examples include glycopyrrolate, amitriptyline (which has the bonus of helping mood and emotional lability), hyoscine/scopolamine patches, and sublingual atropine drops — balanced against side effects like thickened mucus, constipation, urinary retention, and confusion. When oral medications are insufficient or poorly tolerated, botulinum toxin injections into the salivary (parotid/submandibular) glands reduce saliva for months and are well supported; low-dose radiotherapy to the salivary glands is an option in refractory cases. A distinct and sometimes opposite problem is thick, tenacious mucus that is hard to cough up (sometimes worsened by anticholinergics or dehydration); this is managed with good hydration, humidification, mucolytics or nebulized saline, and mechanical cough-assist devices rather than drying agents. Balancing these two secretion problems is a common, very manageable part of bulbar ALS care.

Pseudobulbar affect (PBA) is treatable, and naming it for patients and families is itself therapeutic, since the symptom is often bewildering and mistaken for depression. The dedicated treatment is dextromethorphan plus low-dose quinidine (brand name Nuedexta), an FDA-approved combination shown in randomized trials to reduce the frequency of involuntary laughing/crying episodes in PBA (including in ALS); the quinidine is present only to slow the breakdown of dextromethorphan, so cardiac and drug-interaction precautions apply. Where that combination is unavailable, unsuitable, or for milder cases, antidepressants such as SSRIs or tricyclics (e.g., amitriptyline) are commonly used off-label and can help, sometimes with the added benefit of treating co-existing depression or sialorrhea. Because PBA and depression can coexist and are managed differently, distinguishing them matters. Treatment is individualized to severity, impact, and the person's other symptoms and medications.

Medications aimed at comfort and emotional wellbeing matter throughout ALS, not only at the end. Pain (from cramps, spasticity, immobile joints, and pressure) is treated in a stepwise fashion from simple analgesics up to opioids when needed, alongside physical measures. Breathlessness — especially in advanced disease — is one of the most distressing symptoms, and low-dose opioids (such as morphine) are the mainstay for relieving the sensation of breathlessness, often combined with a benzodiazepine (e.g., lorazepam) when anxiety amplifies it; used appropriately for symptom relief, these improve comfort and are a standard part of palliative care. Depression and anxiety are common understandable responses to the diagnosis and its losses, and are treated with antidepressants (SSRIs and others) and anxiolytics as well as psychological support — and treating them improves quality of life. The same drug can serve more than one purpose (amitriptyline for mood, drooling, and pain; opioids for pain and breathlessness), which clinicians use to simplify regimens. All of this is individualized and best coordinated with palliative care.

The single most important organizing principle of ALS care is the multidisciplinary clinic, where a person sees a coordinated team — neurologist, specialist nurses, respiratory therapist/pulmonologist, dietitian, physical and occupational therapists, speech-language pathologist, social worker, psychologist, and palliative care, often with equipment and assistive-technology support — in one coordinated visit. This both eases the logistical burden on people with declining mobility and ensures problems are anticipated rather than chased. Crucially, the benefit is measurable: population-based studies have found that attending a multidisciplinary ALS clinic is associated with longer survival than care in a general neurology setting — on the order of several extra months, with one Irish study estimating roughly an 8-month advantage and an earlier Italian/US analysis about 7.5 months — along with fewer hospitalizations and better quality of life, without it being attributable to any single intervention. Guidelines therefore recommend that people with ALS be cared for through a coordinated multidisciplinary team. This is why most of the entries below are delivered as part of, or coordinated by, the clinic team.

Physical therapy (physiotherapy) is a mainstay of ALS care aimed at preserving function, comfort, safety, and independence for as long as possible. Regular stretching and range-of-motion exercises help prevent painful joint stiffness, contractures, and 'frozen' shoulders; gait aids, orthotics (such as ankle-foot orthoses for foot drop), and fall-prevention strategies keep people mobile and safe; and positioning and seating advice prevents pressure problems. On exercise specifically, the older fear that activity would 'use up' motor neurons has not held up: moderate, individualized aerobic and resistance exercise appears safe and is associated with modest functional and quality-of-life benefit, provided it avoids overwork and excessive fatigue (which can be counterproductive in weakened muscles). The key principle is realistic goals — therapy maintains and optimizes what remains, eases symptoms, and adapts to progression; it does not reverse weakness. Programs are tailored and updated frequently as the disease changes.

Occupational therapy (OT) focuses on the practical business of daily life — keeping people able to do the everyday tasks they value as ALS changes what their hands, arms, and body can do. OTs assess and provide adaptive equipment (built-up or weighted utensils, button hooks, grab aids, dressing aids, adapted computer access), recommend energy-conservation and task-simplification strategies to manage fatigue, and modify the home and workplace (bathroom safety, ramps, reorganizing frequently used items, accessible controls). They also fit and advise on splints and supports (for example, wrist or neck supports for weakness), help with seating and positioning for comfort and pressure relief, and coordinate with suppliers for wheelchairs and assistive technology. Much of OT's value is anticipatory — introducing aids and adaptations a step ahead of need so transitions are smoother — and in preserving dignity, autonomy, and participation in meaningful activities for as long as possible.

Speech-language pathologists (SLPs) play a dual role in ALS, covering both communication and swallowing. For communication, they assess speech intelligibility over time, teach strategies to maximize clarity (slowing down, over-articulating, conserving voice), and — critically — introduce augmentative and alternative communication (AAC) options and voice banking proactively, before speech becomes unintelligible, so the transition preserves the person's ability to be heard. For swallowing (dysphagia), SLPs evaluate swallow safety (sometimes with instrumented studies), recommend compensatory techniques and posture changes, advise on food textures and thickened liquids to reduce choking and aspiration risk, and help the team judge when nutrition through a feeding tube should be discussed. Because bulbar function often declines steadily, SLP involvement is most valuable when it starts early and continues throughout, anticipating needs rather than reacting to crises.

Losing speech does not have to mean losing the ability to communicate. Augmentative and alternative communication (AAC) spans a spectrum: low-tech options like alphabet/word boards and partner-assisted scanning; text-to-speech apps on tablets and phones; dedicated speech-generating devices; and high-tech access methods for people who can no longer use their hands. Among the most important is eye-gaze (eye-tracking) technology — because ALS usually spares the muscles that move the eyes until very late, a person can control a computer, type messages, speak through synthesized speech, browse, and control their environment using only eye movements. Other access methods include switches activated by small residual movements and, in research settings, emerging brain-computer interfaces. The goal is to match the technology to the person's changing abilities and to set it up before it is urgently needed, so they retain a voice, autonomy, and connection. Funding, training, and ongoing technical support (often coordinated through the clinic and patient organizations) are part of making AAC work in real life.

Voice banking and message banking are proactive steps that let people keep something of their own voice after speech is lost. Voice banking involves recording a set of phrases (sometimes a few hundred) while speech is still reasonably clear; software then builds a personalized synthetic voice that can be loaded onto a speech-generating device, so the AAC system 'speaks' in a voice resembling the person's own rather than a generic one — newer approaches can build a usable voice from relatively short recordings. Message banking complements this by recording specific, personally meaningful phrases, sayings, terms of endearment, or sounds in the person's actual voice, preserved for playback exactly as they sounded. Both are most successful when done early, before bulbar changes degrade the recordings, which is why clinicians and organizations encourage considering them soon after diagnosis even if speech is still normal. Several free and low-cost services and nonprofit programs support the process. For many families, hearing a familiar voice is a profound comfort.

Non-invasive ventilation (NIV) delivers pressurized air through a mask (commonly a BiPAP-type bilevel device), assisting the weakened breathing muscles without any surgical airway. It is typically started for nighttime use when respiratory tests decline or symptoms of nocturnal hypoventilation appear (poor sleep, morning headaches, daytime sleepiness, breathlessness lying flat), and use is extended as needed. NIV is one of the best-evidenced interventions in ALS: a landmark randomized controlled trial (Bourke et al., Lancet Neurology 2006) found that NIV improved both survival and quality of life, extending median survival by about seven months in participants without severe bulbar (swallowing/speech) impairment, while those with severe bulbar weakness gained quality-of-life/sleep benefit without the same survival extension. Guidelines accordingly recommend offering NIV. It requires fitting, acclimatization, and support to tolerate the mask, and settings are adjusted over time. NIV both extends life and relieves the distress of breathlessness, and it sits alongside the advance-care conversation about how far ventilation should go.

A strong cough protects the lungs by clearing mucus and aspirated material; in ALS, weakness of the expiratory (and bulbar) muscles makes the cough ineffective, which contributes to retained secretions, atelectasis (lung collapse), and chest infections — a major cause of illness and hospitalization. Airway clearance support addresses this. Manually assisted coughing (a caregiver-applied abdominal thrust timed with the person's effort) and breath-stacking can boost cough strength. A mechanical insufflation-exsufflation device ('cough assist machine') delivers a deep breath in and then rapidly reverses to a negative pressure, mechanically simulating a cough to move secretions up where they can be cleared or suctioned; it is recommended when cough is weak, especially during respiratory infections. Suction devices, good hydration, humidification, and managing thick secretions complement these. Airway clearance works hand-in-hand with non-invasive ventilation, particularly through illnesses, and is taught to caregivers as part of respiratory care.

As respiratory failure advances beyond what non-invasive ventilation can manage, a major decision arises: whether to proceed to tracheostomy with invasive mechanical ventilation (TIV) — a surgically created airway connected to a ventilator. TIV can prolong life substantially, sometimes for years, and a minority of people with ALS choose it. But it carries heavy implications that must be understood in advance: it usually requires round-the-clock skilled care (often at home with major caregiver and financial burden, or in a facility), it typically ends the ability to speak normally (raising the importance of AAC), it brings risks like infections and secretion management needs, and critically it does not halt the underlying disease — ALS continues to progress, which can eventually lead to a 'locked-in'-like state. Many people, fully informed, choose not to pursue invasive ventilation and instead plan for comfort-focused care; others choose it in line with their values. Because it is so consequential and is sometimes faced in an emergency, guidelines stress discussing it early and revisiting it, so the decision reflects the person's own informed wishes rather than a crisis default. There is no 'right' choice — only the right choice for that individual.

Because weight loss and malnutrition are linked to faster decline, nutrition is managed actively throughout ALS: dietitians track weight and intake, recommend high-calorie/high-protein foods and supplements, and adjust textures for safer swallowing. When swallowing becomes unsafe (choking, aspiration), mealtimes become exhausting, or weight is falling despite efforts, a feeding tube — usually a percutaneous endoscopic gastrostomy (PEG), or a radiologically inserted gastrostomy (RIG) when breathing is weak — is offered. It delivers reliable nutrition, hydration, and a route for medications directly to the stomach, can stabilize weight, and does not prevent eating by mouth for pleasure if that remains safe. A key, evidence-informed point is timing: the procedure is safer when done earlier, while respiratory function (e.g., forced vital capacity) is still relatively preserved, because the sedation and positioning involved are riskier once breathing is significantly impaired. For that reason the conversation is started ahead of crisis, and many teams aim to place the tube before it is urgently needed. The decision remains the person's, informed by the team. Guidelines recommend offering enteral nutrition via gastrostomy to support weight and quality of life.

As weakness spreads, well-matched equipment keeps people mobile, safe, comfortable, and as independent as possible. Mobility supports typically progress over time: ankle-foot orthoses for foot drop, canes and walkers, then manual and ultimately power wheelchairs (often custom-configured with tilt/recline, head and trunk support, and specialized controls as hand function changes). Other commonly needed equipment includes neck/cervical collars or supports for head drop, supportive and pressure-relieving seating and mattresses, hospital beds and patient-lift/hoist systems to enable safe transfers and protect caregivers, bathroom equipment (shower chairs, raised toilet seats, grab bars), and ramps or stair solutions. Because ALS progresses and equipment can take time to obtain and fund, a central principle is anticipation — assessing and ordering aids ahead of need so there is no dangerous gap (for example, a fall risk while waiting for a wheelchair). Occupational and physical therapists, wheelchair-seating specialists, and patient organizations (which often run equipment-loan programs) coordinate this, balancing the person's goals, home environment, and changing abilities.

Environmental control units (ECUs) and smart-home technology restore a measure of independence and safety when movement is severely limited. These systems let a person operate everyday things in their environment — lights, thermostats, door locks and openers, adjustable beds, blinds, televisions, phones, and emergency call systems — through whatever access they still have: switches activated by small residual movements, voice control (while speech allows), or eye-gaze and the same AAC devices used for communication. Mainstream consumer smart-home products and tablets/smartphones with accessibility features have made this far more affordable and flexible than dedicated medical ECUs alone, and they can often be integrated with a person's communication device so a single interface controls both talking and the home. The autonomy this provides — being able to call a caregiver, answer the door, change the TV, or summon help without depending on someone for every small thing — is significant for dignity and psychological wellbeing. Occupational therapists and assistive-technology specialists assess and set these up, adapting access methods as abilities change.

Family caregivers are the backbone of ALS care, and the role is among the most demanding in any chronic illness. Unlike slower diseases, ALS brings rapidly escalating and wide-ranging needs — help with mobility and transfers, personal care, communication, managing ventilation and feeding equipment, medications, and round-the-clock supervision in advanced stages — frequently concentrated on a single spouse, partner, adult child, or parent. The documented consequences are significant: high rates of caregiver burden, depression, anxiety, sleep deprivation, physical strain and injury, social isolation, and financial stress, with burden tending to rise as the patient's function declines and (notably) as cognitive/behavioral changes appear. Recognizing this matters clinically, because caregiver wellbeing directly affects the patient's care and quality of life. Good ALS care therefore treats the caregiver as part of the unit of care — assessing their needs, validating the difficulty, and connecting them to support, training, equipment, respite, and counseling rather than leaving them to cope alone.

Sustaining ALS care over months and years requires deliberately supporting the caregiver, not just the patient. Respite care — through home health aides, adult day programs, trained volunteers, short facility stays, or hospice respite — gives the primary caregiver essential breaks to sleep, recover, work, or simply step away, and is one of the most protective measures against burnout. Sharing the load helps: building a wider circle of family, friends, and community who take on specific tasks (meals, rides, errands, sitting with the person) prevents everything falling on one person, and care-coordination tools or sign-up systems can organize this. Emotional support — individual counseling, caregiver support groups (in person or online), and ALS organization helplines and care services — reduces isolation and provides practical wisdom from others who understand. Caregivers should also be encouraged to tend their own medical and mental health, accept help when offered, and set realistic limits. The principle is simple but easily forgotten under pressure: a depleted caregiver cannot sustain care, so caregiver rest and support are not selfish but necessary.

As ALS erodes speech, families can preserve real, meaningful communication with preparation and patience. Practical strategies include: allowing extra time and not finishing sentences or rushing; using yes/no signals (a blink, look, or small movement) and structured questions; low-tech tools like alphabet and word boards and partner-assisted scanning; and the augmentative and alternative communication (AAC) and eye-gaze devices ideally set up before they were urgently needed (see Therapy). Reducing background noise, facing the person, confirming understanding, and watching facial expression and context all help. Just as important is the relational stance: continuing to include the person in conversations and decisions, speaking to them (not about them in their presence), and preserving humor, affection, and ordinary talk — not only logistics. Because cognition is usually intact, the person remains fully present and wants to participate; communication breakdowns are a technology and patience problem, not a sign they have less to say. Speech-language pathologists coach families on these techniques.

Much daily caregiving is physical, and doing it safely protects both the person with ALS and the caregiver. Transfers and repositioning are a leading cause of caregiver back injury, so patient lifts/hoists, slide sheets, transfer boards, and adjustable hospital beds — plus training from physical/occupational therapists in proper body mechanics — are essential, not optional, especially as the person becomes unable to assist. Because immobility threatens the skin, regular repositioning, pressure-relieving mattresses and cushions, keeping skin clean and dry, and checking pressure points help prevent painful pressure sores. Good positioning also supports breathing (slightly upright eases a weak diaphragm), comfort, and swallowing safety, and gentle range-of-motion movement prevents painful stiff joints and contractures. Other hands-on tasks — assisted feeding (with attention to choking risk), oral and secretion care, managing ventilation masks and feeding tubes, and bathing and toileting — are taught by the clinic team and home-health professionals. Learning correct technique early, and getting the right equipment in place ahead of need, prevents injuries and crises.

ALS asks families to live with loss continuously. 'Anticipatory grief' — mourning losses that are unfolding and still to come — is a normal, often intense part of the experience: grieving each change (a voice, a walk, a shared activity) while the person is still alive and present, alongside love, hope, and the demands of caregiving. Relationships and roles shift, sometimes painfully — a spouse becomes a caregiver, a child cares for a parent, plans for the future are upended — and feelings of fear, anger, guilt, sadness, and exhaustion commonly coexist, even contradictorily. None of this is a failing; it is a human response to an extraordinarily hard situation. What helps is naming these feelings openly, individual or family counseling, support groups and peers who understand, chaplaincy or spiritual support for those who want it, and protecting time for connection and meaning amid the logistics — preserving the relationship, not only managing the disease. Support for grief continues into bereavement, and hospices and ALS organizations offer it. Children in the family have their own needs (see the next entry).

When a parent or close family member has ALS, children and adolescents are deeply affected and do best when adults are honest with them in age-appropriate ways rather than shielding them with silence (which children often fill with frightening or self-blaming explanations). Helpful principles: use clear, truthful language suited to the child's age; reassure them that the illness is nobody's fault and that they are loved and will be cared for; let them ask questions and revisit the conversation over time; keep routines, school, and play as stable as possible; and include them in ways they choose — visiting, helping with small tasks, making memories — without forcing a caregiving role. Watch for signs of distress (changes in mood, sleep, behavior, or school) and involve school counselors and mental-health support as needed. Making memories together (recordings, letters, shared activities, message banking in the person's voice) can be precious for children later. ALS organizations and hospices provide age-specific resources, support groups, and guidance for families on these conversations.

Alongside the medical and emotional toll, ALS imposes a daunting practical and financial load: costly equipment and home modifications, in-home care, transportation, and often the loss of income as the patient and a caregiver reduce or stop working. Getting help navigating this is itself part of good care. Social workers and care coordinators (usually based at the multidisciplinary clinic) and ALS patient organizations are central — they help families understand options, access equipment-loan programs and grants, coordinate home care and respite, and plan ahead. In the United States, an ALS diagnosis qualifies for expedited Social Security Disability Insurance (the waiting period was eliminated for ALS), Medicare access is accelerated, and veterans with ALS are eligible for VA disability benefits given the recognized service connection; Medicaid, charitable assistance, and disability protections may also apply. Legal and financial planning (advance directives, powers of attorney, wills, and benefits paperwork) is best started early while the person can fully participate. Families should be encouraged to ask for help navigating these systems rather than facing them alone — the paperwork and logistics are genuinely complex, and expert guidance both reduces stress and unlocks resources.

Because ALS cannot yet be cured, maximizing comfort, function, and quality of life is the through-line of care from diagnosis onward. In practice this means proactively identifying and treating the symptoms that most affect daily life — pain, breathlessness, muscle cramps and spasticity, drooling and secretions, poor sleep, fatigue, constipation, anxiety and low mood, and the practical frustrations of declining function — using the medications and supportive measures detailed in the Symptoms, Treatment, and Therapy sections. It also means a whole-person stance: respecting the person's autonomy and goals, supporting their roles and relationships, attending to emotional and (for those who want it) spiritual needs, and adapting continuously as the disease changes. This comfort-and-quality-of-life focus is not a switch that flips on 'at the end'; it runs alongside disease-modifying treatment and life-extending interventions throughout, and it is delivered by the whole multidisciplinary team in partnership with the person and their family.

Advance care planning (ACP) carries unusual weight in ALS and is best begun early — soon after the person has had time to absorb the diagnosis — for specific reasons: the disease is relentlessly progressive, it can take away the ability to speak, and a minority develop cognitive/behavioral change that can later cloud complex decisions. Planning ahead, while the person can fully understand and express their wishes, keeps the big decisions in their own hands rather than defaulting to a crisis. ACP in ALS covers the key choices: whether to use non-invasive ventilation and how far to take respiratory support (including whether to pursue tracheostomy/invasive ventilation), whether and when to have a feeding tube, preferences about hospitalization and resuscitation, and preferred place of care and death. The tools include advance directives/living wills, a designated health care proxy or power of attorney, and portable medical-order forms (such as POLST/MOLST in the US) that translate wishes into actionable orders. ACP is not a single conversation but an ongoing one, revisited as the illness and the person's priorities evolve — and it relieves families of having to guess under pressure. Crucially, planning for the worst does not mean giving up hope; it coexists with pursuing treatment and trials.

Among the decisions in ALS, choices about ventilation are the most consequential, which is why they sit at the center of advance care planning. Non-invasive ventilation (NIV) is widely beneficial and extends both survival and comfort (see Therapy), and most people accept it. The harder, deeply personal decision is whether — when NIV is no longer sufficient — to proceed to tracheostomy with invasive mechanical ventilation, which can prolong life substantially but requires constant skilled care, usually ends natural speech, imposes major burdens, and does not stop the disease from continuing to advance. There is genuinely no universally 'right' answer: fully informed people make different choices in line with their own values, circumstances, family situation, and view of acceptable quality of life. What matters is that the choice is informed and the person's own — understanding realistically what each path involves, including the option of declining invasive ventilation in favor of comfort-focused care, which is a legitimate and common choice. Because these decisions can otherwise be forced in an emergency, clinicians raise them early and revisit them, and document them so the person's wishes are honored even if they can no longer speak.

Palliative care is frequently misunderstood as 'end-of-life only' care; in fact it is specialist support aimed at relieving symptoms and improving quality of life for anyone with a serious illness, appropriate at any stage and provided alongside disease-modifying and life-extending treatment. In ALS, early integration of palliative care is recommended and valued because the disease is serious and progressive and brings complex, evolving symptom and support needs. Palliative teams help with difficult-to-manage symptoms (pain, breathlessness, secretions, sleep, anxiety), support emotional and spiritual wellbeing, facilitate advance care planning and goals-of-care conversations, coordinate care across settings, and support the whole family — including through bereavement. Involving palliative care early, while building a relationship over time, generally improves quality of life and ensures that as the disease advances, comfort and the person's priorities are expertly addressed. It complements rather than replaces the ALS clinic and any ongoing treatment or trial participation.

Hospice care provides comprehensive comfort-focused support — symptom management, equipment, nursing, emotional and spiritual care, and family support — usually in the person's own home, for the final phase of the illness (in the US, generally a prognosis of about six months or less). Choosing comfort-focused care, including declining invasive ventilation, is a legitimate and common decision that hospice supports well. An honest, reassuring point that eases a widespread fear: death in ALS is most often peaceful. As the breathing muscles weaken, carbon dioxide gradually rises, which has a calming, sedating effect, and people typically become drowsy and die quietly, frequently during sleep, rather than experiencing a frightening struggle for air. The distressing sensation of breathlessness, when it occurs, is very treatable — low-dose opioids and anxiolytics reliably relieve it — and good palliative and hospice care plans ahead so that medications and support are in place. Families are prepared for what to expect and supported throughout and into bereavement. Knowing this in advance relieves one of the most common and frightening fears people and families carry.

ALS exacts an enormous physical toll, yet a striking and important truth is that quality of life and emotional wellbeing in ALS do not track simply with physical disability: many people, well supported, continue to find meaning, connection, and even joy, and report quality of life that physically able people often underestimate (the so-called 'disability paradox'). Supporting this is part of care. Depression and anxiety are common and treatable (and should not be dismissed as 'understandable' and left unaddressed), and psychological support, counseling, and peer connection help. Beyond treating distress, care attends to what sustains a person: relationships and being included rather than isolated; maintaining roles, interests, and autonomy through assistive technology; communication tools that keep the person an active participant; spiritual or existential support for those who want it; and preserving dignity and the things that bring meaning and pleasure. People with ALS remain fully themselves — their personality, relationships, humor, and inner life intact — and are not reducible to their diagnosis. Centering the person, not just the disease, is both compassionate and a measurable contributor to wellbeing.

Connecting with reputable organizations is one of the most useful early steps for people with ALS and their families — they offer vetted information, care services, equipment-loan programs, support groups, help navigating benefits and insurance, advocacy, and research funding. Major, well-established organizations include: the ALS Association (als.org), which runs a network of certified care centers and local chapters in the United States; I AM ALS (iamals.org), a patient-led organization focused on community, resources, and advocacy; the Muscular Dystrophy Association (mda.org), which supports ALS care and research and operates a resource center; and, in the United Kingdom, the Motor Neurone Disease Association (mndassociation.org), with Scotland served by MND Scotland. Other respected groups include research-focused organizations such as the ALS Therapy Development Institute and various national MND/ALS associations worldwide. A practical caution: because there is a lot of misinformation and some predatory marketing around ALS, rely on these established sources and your clinical team, and verify any specific phone numbers, programs, or local contacts directly on the organization's official website, since details change over time. (This entry deliberately points to official sites rather than reproducing phone numbers that may go out of date.)

Because approved disease-modifying options are limited and the field is moving quickly, many people with ALS consider clinical-trial participation — both for possible personal benefit and to advance knowledge. Trials test new drugs, gene-targeted therapies, devices, and care approaches in phases (early-phase safety studies through large Phase 3 efficacy trials). Legitimate trials are registered on public databases such as ClinicalTrials.gov, are run through universities, ALS/MND clinics, and consortia (e.g., NEALS in North America), have ethical oversight and informed consent, and never charge participants for the experimental treatment itself. Deciding to enroll is personal and worth discussing with the multidisciplinary team: considerations include eligibility (often favoring earlier disease), the chance of receiving placebo, travel and procedure burdens, how it fits with other treatments, and realistic expectations (most experimental therapies ultimately do not prove effective). A crucial caution: be wary of anything marketed as a guaranteed 'cure,' anything that charges large fees for unproven 'treatment,' or 'pay-to-play' stem-cell offerings (see the stem-cell entry) — these are not legitimate trials.

The HEALEY ALS Platform Trial is an innovative, adaptive, multi-arm 'platform' trial coordinated by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. Instead of running each candidate drug as a separate, slow, expensive trial, the platform tests multiple regimens simultaneously under one master protocol that shares a single placebo group and common infrastructure, and can add new treatment arms over time ('perpetual' enrollment). This design substantially reduces cost and time and increases the proportion of participants receiving active drug — addressing long-standing inefficiencies in ALS drug development. Multiple regimens have been evaluated (for example zilucoplan, verdiperstat, CNM-Au8, pridopidine, and later additions), with mixed results so far — most arms have not met their primary endpoints, illustrating how hard ALS is, though some (such as CNM-Au8) generated survival signals that prompted confirmatory studies. The platform itself is widely regarded as an important advance in how ALS therapies are tested, regardless of any individual drug's outcome.

Antisense oligonucleotides (ASOs) are short synthetic molecules, delivered by spinal injection, that reduce production of a specific disease-causing protein by targeting its RNA. Tofersen's success in SOD1-ALS (see Treatment) established the approach and spurred ASOs aimed at other genetic forms — but progress has been sobering, underscoring that each genetic target is different. The most important example is C9orf72, the commonest genetic cause: an ASO against it, BIIB078, was generally safe but showed no clinical benefit (and no improvement on secondary endpoints) in its Phase 1 study, and Biogen/Ionis discontinued it in 2022 — a significant disappointment given how common C9orf72 disease is, and a reminder that lowering a target does not guarantee benefit. On the more hopeful side, an ASO targeting FUS (ulefnersen, formerly jacifusen) is in clinical development for the rare, often young and aggressive FUS-ALS, building on early compassionate-use experience. Other RNA-based strategies (including against ataxin-2/ATXN2 as a modifier) are being explored. The overall message: ASOs are a real, validated modality in ALS, but one that works only when the biology cooperates, and remains investigational beyond SOD1.

Gene therapy aims to treat genetic ALS more durably than repeated antisense injections — for example, using an engineered virus (adeno-associated virus, AAV) to deliver, in a single administration, genetic material that suppresses a mutant gene (such as a microRNA against SOD1) or, in the future, gene-editing tools (like CRISPR) to disable or correct a disease-causing variant. Early human experience exists (including AAV-delivered SOD1 lowering reported in individual patients), and numerous programs are in preclinical or early clinical development. The promise is a one-time, long-lasting treatment; the challenges are substantial and why this remains investigational: safely and efficiently delivering the therapy to motor neurons throughout the brain and spinal cord, avoiding immune reactions to the viral vector, achieving the right amount of gene suppression, and the irreversibility of a permanent change. Gene therapy is among the most actively pursued frontiers for inherited ALS, but it is not yet an available or proven treatment.

Stem cells are an active and frequently misunderstood area of ALS research. The realistic scientific goal is generally not to 'replace' lost motor neurons (extraordinarily difficult, given the long connections required) but to use cells — often mesenchymal stem cells or neural support cells — to protect surviving neurons, reduce inflammation, or deliver neurotrophic (growth) factors. Legitimate trials are ongoing, but results to date are inconclusive: the most prominent product, NurOwn (autologous mesenchymal stem cells modified to secrete growth factors), did not meet its Phase 3 primary endpoint, and in 2023 an FDA advisory committee voted overwhelmingly that the evidence did not establish its effectiveness. This is the honest state of the field — promising biology, no proven stem-cell treatment yet. The crucial public-safety message: predatory 'stem-cell clinics' worldwide market unproven, unapproved, and expensive 'treatments' directly to desperate patients, exploiting a regulatory loophole; these are not legitimate clinical trials, have not been shown to be safe or effective, can cause serious harm, and should be avoided. Scientific and regulatory bodies (FDA, ISSCR) explicitly warn against them. Anyone considering a stem-cell study should verify it through their ALS clinic and public trial registries.

A major barrier in ALS has been the lack of objective biomarkers to diagnose early, predict course, and show quickly whether a treatment is working. Neurofilament light chain (NfL) — a structural protein released into spinal fluid and blood when nerve axons are damaged — has emerged as the most useful: levels are elevated in ALS, correlate with how fast the disease is progressing, carry prognostic information, and can be measured in blood with sensitive assays. NfL's significance was underscored when the FDA granted tofersen accelerated approval based largely on its lowering of plasma NfL as a surrogate 'reasonably likely to predict' clinical benefit — the first time a biomarker drove an ALS approval. Beyond NfL, researchers are developing and validating other biomarkers (imaging measures, other fluid proteins, TDP-43-related markers, and genetic/RNA signatures) to enable earlier diagnosis, patient stratification, and faster, smaller trials that read out on biology rather than waiting years for clinical endpoints. Robust biomarkers are widely seen as one of the keys to accelerating ALS therapeutic progress.

Brain-computer interfaces (BCIs) aim to bypass paralyzed muscles entirely by reading neural activity directly and translating it into communication or control. For ALS — where the desire and ability to think and form language usually remain intact even as movement and speech are lost — this is a potentially transformative direction. Research has progressed rapidly: implanted intracortical BCIs developed by academic teams (including collaborations among UC Davis, Stanford, and Brown) have decoded attempted speech from the brain activity of people with ALS, in recent reports converting neural signals into text and even synthesized voice at high accuracy and, in the latest work, in near real time. These are extraordinary proof-of-concept results that point toward restoring conversation for people who are otherwise 'locked in.' Important caveats: these are early-stage research systems requiring brain surgery and specialized support, studied in very small numbers of participants, not yet available as treatment, and facing challenges of long-term reliability, generalizability, and access. Less invasive BCIs and eye-gaze/AAC systems (see Therapy) remain the practical communication tools today, but implanted BCIs are a fast-moving and hopeful frontier.

Any honest survey of experimental ALS therapies must start with how hard the disease has been to treat. Over several decades, a long list of candidates that looked promising in the lab or in early studies went on to fail large, rigorous clinical trials — including lithium, minocycline (which was actually harmful), ceftriaxone, creatine, dexpramipexole, and many others, alongside the more recent AMX0035/Relyvrio (approved then withdrawn after its confirmatory trial failed) and reldesemtiv. Reasons include the difficulty of translating mouse-model results to humans, the heterogeneity of ALS, late diagnosis (treating after much damage is done), the lack of sensitive biomarkers, and the challenge of designing trials for a variable, fatal disease. This context matters for patients and families: it is the reason to read 'breakthrough' press releases — especially from companies with a financial stake — with cautious skepticism, to weigh early-phase or single-trial results lightly until confirmed, and to value the rare drugs that survive replication. It is not a counsel of despair: the pace of well-designed trials, better biomarkers, genetic targeting, and platform trials is genuinely improving the odds. But realism is part of good information.

CNM-Au8 (Clene) is an orally administered suspension of catalytic gold nanocrystals proposed to improve energy metabolism and protect neurons. Its results illustrate the nuance of interpreting ALS data. In the HEALEY ALS Platform Trial and in the earlier Phase 2 RESCUE-ALS study and expanded-access analyses, CNM-Au8 did NOT meet its primary or key functional/respiratory endpoints — it did not significantly slow decline on the ALSFRS-R — yet it was associated with notable survival signals (a reduced risk of death/ventilation in treated participants) and reductions in the neurofilament biomarker in some analyses. Whether these survival and biomarker signals reflect a real benefit not captured by the function scale, or are statistical artifacts of subgroup and open-label analyses, is exactly the kind of question a confirmatory trial must answer; Clene has indicated plans for a Phase 3 confirmatory study. The honest summary: intriguing survival/biomarker signals, a missed functional primary endpoint, and not-yet-established efficacy. It remains investigational.

Masitinib (AB Science) is an orally administered tyrosine kinase inhibitor thought to act on inflammatory cells (mast cells and microglia/macrophages) that contribute to ALS. Its study AB10015 (a Phase 2b/3 trial of masitinib added to riluzole) reported a statistically significant slowing of ALSFRS-R decline — on the order of a ~27% delay in progression — in a pre-specified subgroup of 'normal progressors,' with associated benefits on quality of life and respiratory function. These results have been genuinely contested: the reliance on a subgroup, methodological questions, and the absence of a clean confirmatory trial led regulators not to approve it for ALS (the European Medicines Agency declined marketing authorization), and it is not an approved or established treatment. AB Science has been conducting a further confirmatory Phase 3 trial. Masitinib is a real example of the interpretive difficulty in ALS: a positive-looking but disputed result that needs independent replication before it could become standard care. Investigational.

An appealing alternative strategy is to treat ALS weakness symptomatically by making the remaining muscle respond more forcefully to whatever nerve signal still reaches it. Cytokinetics developed 'fast skeletal muscle troponin activators' to do this: tirasemtiv showed some effects on muscle function but was limited by tolerability and missed key endpoints (the VITALITY-ALS trial), and its successor reldesemtiv (better tolerated) was advanced to a large Phase 3 trial, COURAGE-ALS (~460 participants). In March 2023, COURAGE-ALS was halted for futility after an interim analysis showed no evidence that reldesemtiv slowed ALSFRS-R decline versus placebo. This line of drugs is instructive: even a mechanistically sensible, well-tolerated approach to symptom (not disease) modification failed to deliver measurable benefit in rigorous testing — another entry in the ALS trial graveyard, and a caution against assuming a good rationale guarantees a good result.

Dexpramipexole is often cited as an emblematic ALS Phase 3 disappointment. After an encouraging Phase 2 study suggested possible benefit on function and survival, Biogen advanced it to EMPOWER, a large, well-conducted Phase 3 trial enrolling 943 people with ALS across many countries. In early 2013 EMPOWER reported clearly negative results: dexpramipexole failed its primary endpoint (a combined measure of function and survival), showed no effect on the individual components or key secondary endpoints, and demonstrated no benefit in any subgroup. Development for ALS was discontinued. The episode reinforced hard lessons about the gap between Phase 2 signals and Phase 3 reality in ALS — small early trials can mislead, and only adequately powered, replicated trials can establish benefit. (Interestingly, dexpramipexole was later repurposed toward an unrelated condition, eosinophilic disease, illustrating how failed candidates sometimes find other uses.)

Drug repurposing — testing medicines already approved for other conditions — is attractive in ALS because of known safety profiles and lower cost, and many such candidates, often aimed at neuroinflammation or cellular stress, have entered trials. Examples include ibudilast (MN-166, an anti-inflammatory/PDE inhibitor) studied in ALS trials; pridopidine (a sigma-1 receptor agonist) which was tested as a regimen within the HEALEY platform trial and did not meet its primary endpoint; and a range of others targeting inflammation, the unfolded-protein response, or metabolism. There has also been interest in agents identified through patient-derived (iPSC) motor-neuron screening, such as ropinirole, with small early-phase studies suggesting possible signals that require confirmation. The overall picture remains one of active investigation without an established winner: most results to date are negative or inconclusive, and these approaches stay firmly investigational. Their value lies in systematically testing plausible mechanisms — and, increasingly, doing so efficiently through platform trials — rather than in any current treatment recommendation.

It is completely understandable that people facing ALS explore every possible avenue, including complementary and alternative medicine (CAM). A clear-eyed framework helps separate the helpful from the useless or harmful. First, distinguish goals: some complementary approaches can genuinely improve comfort, mood, and quality of life (the symptomatic and mind-body therapies below), but as of now none has been proven to slow or stop ALS itself. Second, 'complementary' (used alongside standard care, with the team informed) is very different from 'alternative' (used instead of it) — replacing proven, beneficial treatments like riluzole, ventilation, or nutritional support with unproven remedies can cause real harm. Third, watch for red flags: claims to 'cure' or 'reverse' ALS, secret or proprietary formulas, large out-of-pocket costs, testimonials instead of trial evidence, and providers who discourage standard medical care. Fourth, even 'natural' supplements can interact with medications, cause side effects, and lack quality control. Finally, tell the care team about anything being taken. The reputable resource ALSUntangled, run by ALS clinicians, systematically reviews specific alternative treatments and is a good place to check claims.

Because oxidative stress is part of ALS biology, antioxidant and 'neuroprotective' supplements are among the most commonly tried alternative approaches — but the evidence does not support them as treatments. High-dose coenzyme Q10 (CoQ10) was tested in a well-designed Phase 2 trial and did not show enough benefit to warrant Phase 3. Creatine, despite promising preclinical data, failed to improve outcomes in multiple randomized ALS trials. Vitamin E and other antioxidants have not demonstrated a meaningful effect on survival or progression in controlled studies. Numerous other supplements (various vitamins, curcumin, and many marketed 'ALS formulas') lack credible evidence of disease-modifying benefit. Beyond ineffectiveness, there are real cautions: megadose supplements can have side effects and toxicities, can interact with medications, are poorly regulated for quality and purity, and can be expensive. A reasonable, evidence-based stance is to correct any genuine nutritional deficiencies and maintain good overall nutrition (which matters in ALS) under the dietitian's guidance, while not relying on supplements as treatment. Discuss any supplement with the care team.

Many special diets are promoted for ALS — ketogenic, 'alkaline,' anti-inflammatory, raw-food, and various restrictive cleanses or proprietary protocols. None has been shown in rigorous trials to slow ALS progression, and some carry a specific danger: restrictive or low-calorie regimens can worsen the unintended weight loss that is itself linked to faster decline in ALS. This is where the evidence flips the usual diet narrative. The nutrition fact that genuinely matters in ALS is maintaining body weight and getting enough calories and protein — people who keep their weight up tend to do better, and being underweight is associated with worse outcomes (which is why high-calorie nutrition and timely feeding tubes are part of standard care; see Therapy). So the evidence-based 'diet' advice in ALS is closer to 'eat enough to maintain weight, with help from a dietitian' than to any fashionable restrictive plan. There is early research interest in high-calorie and specific nutritional strategies, but proprietary 'ALS diets' marketed as treatments should be viewed skeptically and discussed with the dietitian and care team — especially before adopting anything restrictive.

Interest in cannabis and CBD (cannabidiol) for ALS is high. The honest evidence picture: there is no good evidence that cannabis or CBD slows or modifies the disease, but cannabinoids have a reasonable rationale and some clinical-trial support for relieving certain symptoms — most notably spasticity (a cannabinoid oromucosal spray, nabiximols, has been studied for spasticity in motor neurone disease with modest benefit), and they are also used by some people for pain, muscle cramps, sleep, anxiety, and appetite. As a symptomatic, quality-of-life tool — not a cure — cannabinoids may have a place for some individuals. Practical cautions apply: legal status varies widely by location; products vary greatly in composition, dose, and quality (especially unregulated CBD products); side effects can include sedation, dizziness, cognitive effects, and (with smoking) respiratory irritation that is unwelcome when breathing is already compromised; and there can be drug interactions. Anyone considering cannabis or CBD for ALS symptoms should discuss it with their care team to weigh benefits, risks, form of administration, and legality, rather than expecting disease-modifying effects.

Mind-body and hands-on complementary therapies are among the safest and most reasonable to consider, not as treatments for ALS but as supports for comfort, mood, and quality of life. Massage and gentle bodywork can ease muscle tension, stiffness, pain, and stress and provide comforting human contact. Mindfulness, meditation, relaxation techniques, and breathing-based practices can help with anxiety, low mood, and coping (psychological wellbeing meaningfully affects quality of life in ALS). Adapted, very gentle yoga or tai-chi-style movement, guided by therapists and matched carefully to a person's abilities and safety, may help with flexibility, relaxation, and a sense of agency. Acupuncture is sometimes used for pain or cramps with limited evidence but general safety in trained hands. Music and art therapy can support emotional expression and connection, especially as communication changes. The key framing: these are complements that can enhance wellbeing alongside standard care, should be adapted to the person's physical limitations and safety (e.g., fatigue, falls, swallowing/breathing), and should be chosen for comfort and quality of life rather than expected to alter the disease. They carry little risk when sensibly applied, which is what distinguishes them from costly or dangerous 'alternative cures.'

Beyond the merely unproven, a category of 'alternative' ALS treatments is actively harmful or predatory, and recognizing them protects patients and families from physical, financial, and emotional harm. Examples include: 'stem-cell clinics' that charge large fees for unapproved, unproven injections (covered in Research Frontiers — these are not legitimate trials and can cause serious injury); chelation therapy and 'detox'/cleanse regimens promoted on the false premise that ALS is caused by toxins to be flushed out; expensive proprietary supplement cocktails and 'miracle cures' sold directly to desperate patients; and any practitioner who urges abandoning standard medical care (riluzole, ventilation, nutrition, the ALS clinic) in favor of their product. Hallmarks to watch for are explicit promises to 'cure,' 'reverse,' or 'heal' ALS, reliance on testimonials rather than published trial evidence, secret or proprietary formulas, pressure and urgency, large out-of-pocket costs, and discouragement of conventional treatment or second opinions. The protective steps are simple: be skeptical of cure claims for a disease that has none, verify anything with the ALS care team and resources like ALSUntangled, and never stop proven treatments for an unproven one. Hope is healthy; exploitation of that hope is what to guard against.